July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A neuroprotective role of IGFBPL1 in glaucoma
Author Affiliations & Notes
  • Xin Wei
    Department of Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Kin-Sang Cho
    Department of Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Shuai Guo
    Department of Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Dong Feng Chen
    Department of Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Xin Wei, None; Kin-Sang Cho, None; Shuai Guo, None; Dong Chen, None
  • Footnotes
    Support  NIH/NEI R01EY025259, P30EY03790, and Lion’s Foundation grant
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 6128. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xin Wei, Kin-Sang Cho, Shuai Guo, Dong Feng Chen; A neuroprotective role of IGFBPL1 in glaucoma
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):6128.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Glaucoma is a complex neurodegenerative disease that affects 80 million people world-wide. Loss of retinal ganglion cells (RGCs) and degeneration of the optic nerve are the major pathological hallmarks. We discovered recently that insulin-like growth factor binding protein like-1 (IGFBPL-1) , a member of the IGFBP superfamily proteins, promoted the regeneration of RGC axons in vitro and in vivo through binding to IGF-1. Here we examined the effect of IGFBPL1 in a mouse model of glaucoma.

Methods : We induced elevation of intraocular pressure (IOP) by anterior chamber injection of microbeads. Mice were then divided into two groups: one group received intravitreous injections of IGFBPL-1 and the other group received saline injections on day 3, 10 and 17 after the microbead injection. Retina/RGC function and mouse visual behavior (visual acuity and contrast sensitivity) were assessed by electroretinogram (ERG) positive scotopic threshold response (pSTR) and optomotor kinetic (OMR) assay on day 0 and then every two weeks until sacrifice. Mice were sacrificed at 8 weeks post microbead injection and RGC and axon loss was quantified.

Results : Elevated IOP induced RGC and visual function decline as measured by ERG/pSTR and OMR. Administration of IGFBPL1 significantly improved pSTR and visual behavior compared to saline-injected group. Moreover, after induce high IOP for 8 weeks, the RGCs loss rate in Saline group is 42.3±3.2%, which is 19.2±1.9% in IGFBPL-1 group.

Conclusions : IGFBPL1 presents a strong neuroprotective effect for RGCs against glaucomatous neural damage. The finding suggests a new therapeutic strategy for RGC protection and rescuing vision in glaucoma.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×